HIV transmission and the cost-effectiveness of methadone maintenance
Tóm tắt
OBJECTIVES: This study determined the cost-effectiveness of expanding methadone maintenance treatment for heroin addiction, particularly its effect on the HIV epidemic. METHODS: We developed a dynamic epidemic model to study the effects of increased methadone maintenance capacity on health care costs and survival, measured as quality-adjusted life-years (QALYs). We considered communities with HIV prevalence among injection drug users of 5% and 40%. RESULTS: Additional methadone maintenance capacity costs $8200 per QALY gained in the high-prevalence community and $10,900 per QALY gained in the low-prevalence community. More than half of the benefits are gained by individuals who do not inject drugs. Even if the benefits realized by treated and untreated injection drug users are ignored, methadone maintenance expansion costs between $14,100 and $15,200 per QALY gained. Additional capacity remains cost-effective even if it is twice as expensive and half as effective as current methadone maintenance slots. CONCLUSIONS: Expansion of methadone maintenance is cost-effective on the basis of commonly accepted criteria for medical interventions. Barriers to methadone maintenance deny injection drug users access to a cost-effective intervention that generates significant health benefits for the general population.
Từ khóa
Tài liệu tham khảo
Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report. Atlanta, Ga: Centers for Disease Control and Prevention; 1998.
Latkin CA, 1998, Public Health Rep., 113, 151
Vlahov D, 1998, Public Health Rep., 113, 75
Metzger DS, 1993, J Acquir Immune Defic Syndr., 6, 1049
Metzger DS, 1998, Public Health Rep., 113, 97
Hartel DM, 1998, Public Health Rep., 113, 107
The mayor's crusade against methadone [editorial]. New York Times. August 18, 1998:A1.
Gerstein DR, Johnson RA, Harwood H, Fountain D, Suter N, Malloy K. Evaluating Recovery Services: The California Drug and Alcohol Treatment Assessment (CALDATA). Sacramento: California Department of Alcohol and Drug Programs; 1994.
Harwood HJ, 1988, NIDA Res Monogr., 86, 209
Harwood JJ, 1995, Res Law Policy Stud., 3, 191
Hethcote H. Modeling AIDS prevention programs in a population of homosexual men. In: Kaplan EH, Brandeau ML, eds. Modeling the AIDS Epidemic: Planning, Policy, and Prediction. New York, NY: Raven Press; 1994:91-108.
Paltiel AD, 1991, J Acquir Immune Defic Syndr., 4, 795
Kahn JG, Washington AE, Showstack JA, Berlin M, Phillips K, Watson S. Updated Estimates of the Impact and Cost of HIV Prevention in Injection Drug Users. Report prepared for Centers for Disease Control and Prevention. San Francisco: Institute for Health Policy Studies, University of California; 1992.
Kaplan EH, 1992, J Acquir Immune Defic Syndr., 5, 1116
The Effectiveness of Drug Abuse Treatment: Implications for Controlling AIDS/HIV Infection. Washington, DC: US General Accounting Office; 1990.
Methadone Maintenance: Some Treatment Programs Are Not Effective; Greater Federal Oversight Needed. Washington, DC: US General Accounting Office; 1990.
Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996.
Barnett PG, Rodgers JH. The Cost of Substance Abuse Treatment: A Multivariate Cost Function Using the NDATUS. Palo Alto, Calif: VA Health Care System; 1998.
Statistical Abstract of the United States. Washington, DC: Bureau of the Census, US Dept of Commerce; 1997.
McNaghten AD. The effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS. Paper presented at: Fifth Conference on Retroviruses and Opportunistic Infections; February 2, 1998; Chicago, Ill.
Bayoumi AM, Redelmeier DA. Economic Methods for Measuring the Quality of Life Associated With HIV Infection. Toronto, Ontario: University of Toronto; 1999.
Turner B, 1995, J Acquir Immune Defic Syndr., 9, 371
Pedersen D, 1997, Newsweek., 60
Richardson L. Addicts avoid AIDS drugs, fearing they affect methadone. New York Times. July 19, 1998:A1.
Owens D. Economic evaluations of HIV screening. In: Holtgrave DR, ed. Handbook of HIV Prevention Policy Analysis. New York, NY: Plenum Press; 1998:81-101.
Zweben JE, 1990, West J Med., 152, 588
Richter AR, Brandeau ML, Owens DK. Policy analysis of preventive HIV interventions targeted to adolescents: an application of STELLA. Paper presented at: Simulation in the Medical Sciences Conference: Proceedings of the 1996 Western Multiconference; January 1996; San Diego, Calif.
Kamlet MS, Wade M, Kupfer DJ, Frank E. Cost-utility analysis of maintenance treatment for recurrent depression: a theoretical framework and numerical illustration. In: Frank RG, Manning WG, eds. Economics and Mental Health. Baltimore, Md: Johns Hopkins University Press; 1992:267-291.
Substance Abuse and Mental Health Services Administration. National Drug and Alcoholism Treatment Unit Survey: 1991 Main Findings Report. Rockville, Md: US Dept of Health and Human Services; 1993. DHHS publication PHS (SMA) 93-2007.
Rettig RA, Yarmolinsky A. Federal Regulation of Methadone Treatment. Washington, DC: National Academy Press; 1995.
Battjes RJ, 1991, J Acquir Immune Defic Syndr., 4, 1148
Battjes RJ, 1995, J Acquir Immune Defic Syndr., 10, 90
Laumann EO, Gagnon JH, Michael RT, Michaels S. The Social Organization of Sexuality: Sexual Practices in the United States. Chicago, Ill: University of Chicago Press; 1994.
Samuel MC, Mohr MS, Speed TP, Winkelstein W. Infectivity of HIV by anal and oral intercourse among homosexual men: estimates from a prospective study in San Francisco. In: Kaplan EH, Brandeau ML, eds. Modeling the AIDS Epidemic: Planning, Policy, and Prediction. New York, NY: Raven Press; 1994:423-438.
Cheng FK, 1995, Clin Perform Qual Health Care., 3, 147
Hogg RS, 1999, CMAJ., 160, 659
Bureau of Labor Statistics. Consumer Price Index. Washington, DC: US Dept of Labor; 1998.